Shopping cart ITEMS
 modern scholarly publishers in the finest tradition
Login Register
Home
Books
Journals
References
A-Z Index
Author Index
For Our Authors
User Area
Shopping Cart
Contact
Electronic Data Center

Critical Reviews™ in Eukaryotic Gene Expression

 

ISSN for PRINT: 1045-4403

Institutional price:

$708.00

Issues per year:

4

For Online Access

Best Paper Award Selection - Editorial Board Site

Add subscription to shopping cart

2006, Volume16

Issue 3

  90 pages  

   

click 'Save as...' here to save XML metadata

Issue price - $169.00  

Add to shopping cart

  • Retinoid Targets for the Treatment of Cancer
  • Zivjena Buletic
    Department of Biochemistry, Temple University School of Medicine, Philadelphia, PA 19140

    Kenneth J. Soprano
    Department of Microbiology & Immunology, and Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA 19140

    Dianne Robert Soprano
    Department of Biochemistry, and Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA 19140


    ABSTRACT

    Retinoic acid (RA), the most potent natural retinoid, is essential for normal cell growth and differentiation. The RA signaling pathway is multistep, involving the precise regulation of retinoid levels and the control of RA-dependent gene expression in target cells. Within this complex scheme, there are many different aberrations in the RA signaling pathway of tumor cells that have been found to be associated with abnormal cell growth and tumorigenesis. This article reviews the normal pathways of RA signaling, followed by a discussion of the various sites that have been implicated in tumorigenesis and targeted for drug development. Currently, there are several retinoids and one rexinoid approved for the treatment of specific cancers. Future experimentation in drug discovery will continue to explore the efficacy of retinoids/rexinoids, either alone or in combination with other chemotherapeutic agents and/or chromatin remodeling agents, and the development of agents to modulate RA metabolism within cells. It is likely that different drug treatments will be developed that are specifically tailored to the unique point(s) in the RA signaling pathways that are aberrant in specific types of tumor cells.

    Download article, 193-210 pages

    Article price - $35.00  

    Add to shopping cart

      Next article >>

    Designed by offsiteteam Designed by offsiteteam Designed by offsiteteam
    Begell House Inc.
    50 Cross Highway,
    Redding, CT 06896
    TEL (203) 938 1300
    FAX (203) 938 1304
    orders@begellhouse.com